Use of a lentivirus/VSV pseudotype virus for highly efficient genetic redirection of human peripheral blood lymphocytes

Nature Protocols

Volumn 1, Issue 6, 2007, Pages 2688-2700

  Simmons, Anthony ^a   Jantz, Kristina ^a  

^a Division of Pediatric Cardiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; VIRUS ENVELOPE PROTEIN;

ARTICLE; GENETIC ENGINEERING; GENETICS; HUMAN; IMMUNOLOGY; LENTIVIRINAE; LYMPHOCYTE; METHODOLOGY; VESICULAR STOMATITIS VIRUS;

ANTIGENS, CD28; ANTIGENS, CD3; GENETIC ENGINEERING; HUMANS; LENTIVIRUS; LYMPHOCYTES; VESICULAR STOMATITIS-INDIANA VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 34548836554     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2006.409     Document Type: Article

References (31)

1. Eshhar, Z. Tumor-specific T-bodies: Towards clinical application. Cancer Immunol. Immunother. 45, 131-136 (1997).
2. Gross, G., Gorochov, G., Waks, T. & Eshhar, Z. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant. Proc. 21, 127-130 (1989).
3. Pinthus, J.H. et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res. 63, 2470-2476 (2003).
4. Pinthus, J.H. et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J. Clin. Invest. 114, 1774-1781 (2004).
5. Schule, S. et al. Selective gene transfer to T lymphocytes using coreceptor-specific [MLV(HIV)] pseudotype vectors in a transgenic mouse model. Virology 351, 237-247 (2006).
6. Hombach, A. et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J. Immunol. 167, 6123-6131 (2001).
7. Hombach, A. et al. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Int. J. Cancer 88, 115-120 (2000).
8. Hombach, A. et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther. 6, 300-304 (1999).
9. Haynes, N.M. et al. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J. Immunol. 166, 182-187 (2001).
10. Haynes, N.M. et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100, 3155-3163 (2002).
11. Doherty, P.C., Tripp, R.A. & Sixbey, J.W. Evasion of host immune responses by tumours and viruses. Ciba Found. Symp. 187, 245-256 (1994).
12. Simmons, A. & Tscharke, D.C. Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: Implications for the fate of virally infected neurons. J. Exp. Med. 175, 1337-1344 (1992).
13. Liu, T., Khanna, K.M., Carriere, B.N. & Hendricks, R.L. Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons. J. Virol. 75, 11178-11184 (2001).
14. Liu, T., Khanna, K.M., Chen, X., Fink, D.J. & Hendricks, R.L. CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J. Exp. Med. 191, 1459-1466 (2000).
15. Ory, D.S., Neugeboren, B.A. & Mulligan, R.C. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA 93 11400-11406 (1996).
16. Yang, Y. et al. Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein. Hum. Gene Ther. 6, 1203-1213 (1995).
17. Arai, T. et al. A new system for stringent, high-titer vesicular stomatitis virus G protein-pseudotyped retrovirus vector induction by introduction of Cre recombinase into stable prepackaging cell lines. J. Virol. 72, 1115-1121 (1998).
18. Kahl, C.A., Pollok, K., Haneline, L.S. & Cornetta, K. Lentiviral vectors pseudotyped with glycoproteins from Ross River and vesicular stomatitis viruses: Variable transduction related to cell type and culture conditions. Mol. Ther. 11, 470-482 (2005).
19. Logan, A.C. et al. Factors influencing the titer and infectivity of lentiviral vectors. Hum. Gene Ther. 15, 976-988 (2004).
20. Kafri, T. Gene delivery by lentivirus vectors an overview. Methods Mol. Biol. 246, 367-390 (2004).
21. Verdier, F. & Descotes, J. Preclinical safety evaluation of human gene therapy products. Toxicol. Sci. 47, 9-15 (1999).
22. Russell, D.W., Berger, M.S. & Miller, A.D. The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines. Hum. Gene Ther. 6, 635-641 (1995).
23. Rigg, R.J. et al. A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety. Virology 218, 290-295 (1996).
24. Croyle, M.A. et al. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol. 78, 912-921 (2004).
25. Chen, J., Dave, S.K. & Simmons, A. Prevention of genital herpes in a guinea pig model using a glycoprotein D-specific single chain antibody as a microbicide. Virol. J. 1, 11 (2004).
26. Simmons, A., Robert, W.P., Kolokoltsov, A.A. & Davey, R.A. Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro. Virol. J. 3, 8 (2006).
27. Schagen, F.H., Rademaker, H.J., Fallaux, F.J. & Hoeben, R.C. Insertion vectors for gene therapy. Gene Ther. 7, 271-272 (2000).
28. Bartz, S.R. & Vodicka, M.A. Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein. Methods 12, 337-342 (1997).
29. Hardy, D.A. & Ling, N.R. Effects of some cellular antigens on lymphocytes and the nature of the mixed lymphocyte reaction. Nature 221, 545-548 (1969).
30. Schwarz, M.R., Tyler, R.W. & Everett, N.B. Mixed lymphocyte reaction: An in vitro test for antilymphocytic serum activity. Science 160, 1014-1017 (1968).
31. Steinman, R.M. & Inaba, K. Stimulation of the primary mixed leukocyte reaction. Crit. Rev. Immunol. 5, 331-348 (1985).